# Prevention of Atrial Fibrillation by Low-dose Landiolol Administration After Cardiac Surgery

Study · id `cardio:ct-nct04607122` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04607122](<https://clinicaltrials.gov/study/NCT04607122>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04607122

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 400 participants.

## Technical summary

Registry record NCT04607122. Randomized; quadruple masking; primary purpose prevention. Start 2021-01-27 (actual); primary completion 2023-06-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 400 participants (enrolled count; ClinicalTrials.gov record NCT04607122, source copy `cardio:ctgov-nct04607122-2026-04-08`, retrieved 2026-10-26)
- Started: 2021-01-27 (actual) (ClinicalTrials.gov record NCT04607122, source copy `cardio:ctgov-nct04607122-2026-04-08`, retrieved 2026-10-26)
- Primary completion: 2023-06-30 (actual) (ClinicalTrials.gov record NCT04607122, source copy `cardio:ctgov-nct04607122-2026-04-08`, retrieved 2026-10-26)
- Completion: 2023-07-22 (actual) (ClinicalTrials.gov record NCT04607122, source copy `cardio:ctgov-nct04607122-2026-04-08`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT04607122, source copy `cardio:ctgov-nct04607122-2026-04-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04607122-2026-04-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Prevention of Atrial Fibrillation by Low-dose Landiolol Administration After Cardiac Surgery
- Acronym: LANDIPROTEC
- Condition: Atrial Fibrillation
- Condition: Cardiac Surgery
- Intervention (Drug): Landiolol
- Intervention (Drug): Saline
- Lead sponsor: CMC Ambroise Paré
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Low dose of landiolol does not prevent postoperative atrial fibrillation after cardiac surgery in non-Asian patients: a multicentre randomised study (`cardio:pubmed-41203473`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2e0ea01f9b63f82d1b29c14563a7373c85f640ec852fa4c41d18c1df699b0c41
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
